Charleen D Adams1. 1. Beckman Research Institute, Duarte, CA, USA.
Abstract
BACKGROUND: Alzheimer's disease is a devastating neurodegenerative disorder. Its worldwide prevalence is over 24 million and is expected to double by 2040. Finding ways to prevent its cognitive decline is urgent. METHODS: A two-sample Mendelian randomization study was performed instrumenting glutamine, which is abundant in blood, capable of crossing the blood-brain barrier, and involved in a metabolic cycle with glutamate in the brain. RESULTS: The results reveal a protective effect of circulating glutamine against Alzheimer's disease (inverse-variance weighted method, odds ratio per 1-standard deviation increase in circulating glutamine = 0.83; 95% CI 0.71, 0.97; P = 0.02). CONCLUSION: These findings lend credence to the emerging story supporting the modifiability of glutamine/glutamate metabolism for the prevention of cognitive decline. More circulating glutamine might mean that more substrate is available during times of stress, acting as a neuroprotectant. Modifications to exogenous glutamine may be worth exploring in future efforts to prevent and/or treat Alzheimer's disease.
BACKGROUND: Alzheimer's disease is a devastating neurodegenerative disorder. Its worldwide prevalence is over 24 million and is expected to double by 2040. Finding ways to prevent its cognitive decline is urgent. METHODS: A two-sample Mendelian randomization study was performed instrumenting glutamine, which is abundant in blood, capable of crossing the blood-brain barrier, and involved in a metabolic cycle with glutamate in the brain. RESULTS: The results reveal a protective effect of circulating glutamine against Alzheimer's disease (inverse-variance weighted method, odds ratio per 1-standard deviation increase in circulating glutamine = 0.83; 95% CI 0.71, 0.97; P = 0.02). CONCLUSION: These findings lend credence to the emerging story supporting the modifiability of glutamine/glutamate metabolism for the prevention of cognitive decline. More circulating glutamine might mean that more substrate is available during times of stress, acting as a neuroprotectant. Modifications to exogenous glutamine may be worth exploring in future efforts to prevent and/or treat Alzheimer's disease.
Authors: James Yarmolinsky; Caroline L Relton; Artitaya Lophatananon; Kenneth Muir; Usha Menon; Aleksandra Gentry-Maharaj; Axel Walther; Jie Zheng; Peter Fasching; Wei Zheng; Woo Yin Ling; Sue K Park; Byoung-Gie Kim; Ji-Yeob Choi; Boyoung Park; George Davey Smith; Richard M Martin; Sarah J Lewis Journal: PLoS Med Date: 2019-08-07 Impact factor: 11.069
Authors: Johannes Kettunen; Ayşe Demirkan; Peter Würtz; Harmen H M Draisma; Toomas Haller; Rajesh Rawal; Anika Vaarhorst; Antti J Kangas; Leo-Pekka Lyytikäinen; Matti Pirinen; René Pool; Antti-Pekka Sarin; Pasi Soininen; Taru Tukiainen; Qin Wang; Mika Tiainen; Tuulia Tynkkynen; Najaf Amin; Tanja Zeller; Marian Beekman; Joris Deelen; Ko Willems van Dijk; Tõnu Esko; Jouke-Jan Hottenga; Elisabeth M van Leeuwen; Terho Lehtimäki; Evelin Mihailov; Richard J Rose; Anton J M de Craen; Christian Gieger; Mika Kähönen; Markus Perola; Stefan Blankenberg; Markku J Savolainen; Aswin Verhoeven; Jorma Viikari; Gonneke Willemsen; Dorret I Boomsma; Cornelia M van Duijn; Johan Eriksson; Antti Jula; Marjo-Riitta Järvelin; Jaakko Kaprio; Andres Metspalu; Olli Raitakari; Veikko Salomaa; P Eline Slagboom; Melanie Waldenberger; Samuli Ripatti; Mika Ala-Korpela Journal: Nat Commun Date: 2016-03-23 Impact factor: 14.919
Authors: Caroline Madeira; Charles Vargas-Lopes; Carlos Otávio Brandão; Taylor Reis; Jerson Laks; Rogerio Panizzutti; Sergio T Ferreira Journal: Front Psychiatry Date: 2018-11-06 Impact factor: 4.157
Authors: Gayani Petersingham; Mohammad S Zaman; Adam J Johnson; Narsimha Reddy; Allan M Torres; Ming J Wu Journal: Biometals Date: 2022-05-31 Impact factor: 3.378
Authors: JianXiang Weng; Isabella H Muti; Anya B Zhong; Pia Kivisäkk; Bradley T Hyman; Steven E Arnold; Leo L Cheng Journal: Metabolites Date: 2022-02-15